Contacts
Media Contact:
858-366-6900
media@tandemdiabetes.com
Investor Contact:
858-366-6900
IR@tandemdiabetes.com
Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, plans to release its fourth quarter and full year 2023 results after the financial markets close on Wednesday, February 21, 2024. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its fourth quarter and full year 2023 financial and operating results.
A live webcast of the call will be available on Tandem Diabetes Care’s Investor Center website located at http://investor.tandemdiabetes.com in the “Events & Presentations” section. To access the call by phone, please use this link (https://register.vevent.com/register/BIa95db72e0b404258a57afd8b48cc6915) and you will be provided with dial-in details, including a personal pin.
An archive of the webcast will be available for 30 days following the event on Tandem Diabetes Care’s Investor Center website located at http://investor.tandemdiabetes.com in the “Events & Presentations” section.
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc., a global insulin delivery and diabetes technology company based in San Diego, California, creates new possibilities for people living with diabetes, their loved ones, and healthcare providers through a positively different experience. The Company’s human-centered approach to design, development, and support delivers innovative products and services for people who use insulin. Tandem manufactures and sells the t:slim X2 insulin pump with Control-IQ technology. For more information, visit tandemdiabetes.com.
Tandem Diabetes Care, t:slim X2, and Control-IQ are either registered trademarks or trademarks of Tandem Diabetes Care, Inc. in the US and/or other countries.
Follow Tandem Diabetes Care on Twitter @tandemdiabetes; use #tslimX2 and #TandemDiabetes.
Follow Tandem Diabetes Care on Facebook at www.facebook.com/TandemDiabetes.
Follow Tandem Diabetes Care on LinkedIn at https://www.linkedin.com/company/tandemdiabetes.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240122318175/en/
Related news for (TNDM)
- Tandem Diabetes Care Announces Agreement with Abbott for Integration of Automated Insulin Delivery Systems with Future Glucose-Ketone Sensor
- Tandem Diabetes Care Announces FDA Clearance of Control-IQ+ Automated Insulin Delivery Technology for People with Type 2 Diabetes
- Tandem Diabetes Care Enters Multi-Year Research Collaboration with UVA Center for Diabetes Technology for Development of Advanced Insulin Delivery Systems
- tandem diabetes care to release updated ios t:connect mobile app for t:slim x2 insulin pump users impacted by march 2024 nationwide recall
- 24/7 Market News- Tandem Diabetes Care Reports Q2 2024 Financial Results and Increases Full Year 2024 Sales Guidance